Sartorius Stedim Biotech SA
DIM: XPAR (FRA)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| LOCK|^k | LOCK|ld | LOCK|K%$%&F! |
Sartorius Stedim Earnings: Guidance Confirmed, Equipment Recovery Awaited; Shares Undervalued
Sartorius Stedim reported first-quarter constant-currency sales growth of 7.9%, with both segments contributing healthy numbers. Underlying EBITDA margin declined 10 basis points to 30.7%. Management confirmed its full-year guidance.
